Welcome on the official webpage of the BIOSTEMI TRIAL.

Welcome on the official webpage of the BIOSTEMI TRIAL.

BIOSTEMI TRIAL

A prospective, multi-center, randomized, controlled superiority trial designed to assess the safety and efficacy of the ultrathin-strut Orsiro® Hybrid sirolimus-eluting stent with biodegradable-polymer compared with the state-of-the-art thin-strut Xience® (Xience Xpedition® or Xience Alpine®) everolimus-eluting stent with biocompatible permanent polymer in patients with acute STEMI undergoing primary PCI.

Study design :  Randomized, controlled, open-label trial
Intervention : Orsiro® Hybrid sirolimus-eluting stent with biodegradable-polymer versus  Xience® (Xience Xpedition® or Xience Alpine®) everolimus-eluting stent with biocompatible permanent polymer
Number of patients : 1,250
Patients population : all-comers patients with acute STEMI undergoing primary PCI.
Length of study : 2 years recruitment period and 2 years follow-up period

Enrolment status (30 october 2016) :

novembre1

 

Enrolment per study center (30 october 2016) :

novembre4

Enrolment status per study center: last month (30 october 2016) :

novembre5